An analysis of recent approved and failed marketing applications for new drugs evaluated by the European Medicines Agency highlights the factors that are most likely to be associated with non-approval.
- Michelle Putzeist
- Aukje K. Mantel-Teeuwisse
- Hans-Georg Eichler